Nasdaq · CIK 0001027838
TCMD TACTILE SYSTEMS TECHNOLOGY INC
Insider trading from SEC Form 4. Last filing Aug 12, 2025. Close $22.44 on Oct 9, 2026, +58% from the 52-week low and -32% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
TCMDOct 9, 2026 · close 22.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TACTILE SYSTEMS TECHNOLOGY INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Sheri Louise Dodd Chief Executive Officer sell | $96k 7,762 shares | -4% | +30% from low-37% from high | |
| 22Weak | Elaine M. Birkemeyer Chief Financial Officer sell | $29k 2,921 shares | -3% | +2% from low-50% from high | |
| 45Moderate | Sheri Louise Dodd Chief Executive Officer sell | $31k 3,149 shares | -2% | +1% from low-50% from high | |
| 15Weak | William W Burke director sell | $32k 3,300 shares | -6% | +1% from low-50% from high | |
| 15Weak | Elaine M. Birkemeyer Chief Financial Officer sell | $30k 2,066 shares | -2% | - | |
| 33Weak | Kristie Burns Sr. VP Mktg & Clinical Affairs sell | $93k 6,468 shares | -8% | - | |
| 17Weak | Elaine M. Birkemeyer Chief Financial Officer sell | $56k 3,778 shares | -4% | - | |
| 31Weak | Kristie Burns Sr. VP Mktg & Clinical Affairs sell | $71k 4,830 shares | -5% | - |
Transactions
The last 24 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | Sheri Louise Dodd Chief Executive Officer | SOpen-market sale Common Stock | -7,762 | $12.36 | $96k | 173,479 | Aug 12, 2025 |
| May 12, 2025 | Elaine M. Birkemeyer Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -2,921 | $9.94 | $29k | 99,111 | May 14, 2025 |
| May 8, 2025 | Sheri Louise Dodd Chief Executive Officer | SOpen-market sale Common Stock | -3,149 | $9.83 | $31k | 181,241 | May 12, 2025 |
| May 7, 2025 | Valerie L. Asbury director | AGrant or award Common Stock | +16,078 | $0.00 | $0 | 48,822 | May 9, 2025 |
| May 7, 2025 | William W Burke director | AGrant or award Common Stock10b5-1 | +16,078 | $0.00 | $0 | 51,820 | May 9, 2025 |
| May 7, 2025 | Raymond Huggenberger director | AGrant or award Common Stock | +16,078 | $0.00 | $0 | 56,320 | May 9, 2025 |
| May 7, 2025 | Laura G. King director | AGrant or award Common Stock | +16,078 | $0.00 | $0 | 19,048 | May 9, 2025 |
| May 7, 2025 | David Brent Shafer director | AGrant or award Common Stock | +16,078 | $0.00 | $0 | 48,822 | May 9, 2025 |
| May 7, 2025 | Boyd Vindell Washington director | AGrant or award Common Stock | +16,078 | $0.00 | $0 | 35,247 | May 9, 2025 |
| May 7, 2025 | Carmen B Volkart director | AGrant or award Common Stock | +16,078 | $0.00 | $0 | 37,698 | May 9, 2025 |
| May 8, 2025 | William W Burke director | SOpen-market sale Common Stock10b5-1 | -3,300 | $9.67 | $32k | 48,520 | May 9, 2025 |
| Feb 25, 2025 | Kristie Burns Sr. VP Mktg & Clinical Affairs | SOpen-market sale Common Stock | -6,468 | $14.40 | $93k | 77,540 | Feb 27, 2025 |
| Feb 25, 2025 | Elaine M. Birkemeyer Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -2,066 | $14.51 | $30k | 102,032 | Feb 27, 2025 |
| Feb 20, 2025 | Elaine M. Birkemeyer Chief Financial Officer | AGrant or award Common Stock10b5-1 | +3,446 | $0.00 | $0 | 64,741 | Feb 24, 2025 |
| Feb 20, 2025 | Kristie Burns Sr. VP Mktg & Clinical Affairs | AGrant or award Common Stock | +3,359 | $0.00 | $0 | 68,128 | Feb 24, 2025 |
| Feb 20, 2025 | Sheri Louise Dodd Chief Executive Officer | AGrant or award Common Stock | +20,108 | $0.00 | $0 | 118,721 | Feb 24, 2025 |
| Feb 20, 2025 | Laura G. King director | AGrant or award Common Stock | +2,970 | $0.00 | $0 | 2,970 | Feb 24, 2025 |
| Feb 20, 2025 | Elaine M. Birkemeyer Chief Financial Officer | AGrant or award Common Stock10b5-1 | +6,887 | $0.00 | $0 | 71,628 | Feb 24, 2025 |
| Feb 20, 2025 | Kristie Burns Sr. VP Mktg & Clinical Affairs | AGrant or award Common Stock | +4,131 | $0.00 | $0 | 72,259 | Feb 24, 2025 |
| Feb 20, 2025 | Sheri Louise Dodd Chief Executive Officer | AGrant or award Common Stock | +65,669 | $0.00 | $0 | 184,390 | Feb 24, 2025 |
| Feb 20, 2025 | Elaine M. Birkemeyer Chief Financial Officer | AGrant or award Common Stock10b5-1 | +36,248 | $0.00 | $0 | 107,876 | Feb 24, 2025 |
| Feb 20, 2025 | Kristie Burns Sr. VP Mktg & Clinical Affairs | AGrant or award Common Stock | +16,579 | $0.00 | $0 | 88,838 | Feb 24, 2025 |
| Feb 24, 2025 | Elaine M. Birkemeyer Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -3,778 | $14.70 | $56k | 104,098 | Feb 24, 2025 |
| Feb 24, 2025 | Kristie Burns Sr. VP Mktg & Clinical Affairs | SOpen-market sale Common Stock | -4,830 | $14.65 | $71k | 84,008 | Feb 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Valerie L. Asburydirector
- William W Burkedirector
- Elaine M. BirkemeyerChief Financial Officer
- Kristie BurnsSr. VP Mktg & Clinical Affairs
- Sheri Louise DoddChief Executive Officer
- Raymond Huggenbergerdirector
- Laura G. Kingdirector
- David Brent Shaferceo, chair, officer, director, other
- Carmen B Volkartdirector
- Boyd Vindell Washingtondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.